AstraZeneca Collaborates with DeepMatter for Optimization of Compound Synthesis Leveraging AI and Machine Learning

Shots:

• AstraZeneca team up with DeepMatter to utilize its digital technologies enabled with ML and AI to improve the productivity and reproducibility of compound synthesis
• The collaboration leverages DeepMatter’s Digital Glassware data collection and structuring technology to be used with AstraZeneca’s automated compound synthesis platform
• Digital Glassware enables users to capture and analyze a rich array of information about their chemical reaction, leverage AI and ML to increase the certainty of producing high quality and choice of candidate drug candidates

Click here to­ read full press release/ article | Ref: DeepMatter | Image: UK Investor Magazine